Practical Management of Novel Bladder Cancer Therapy with Antibody-drug Conjugates and Immunotherapies

Presentation Goal: Increase practical knowledge, application, and awareness of management strategies for patients receiving combination therapy with Enfortumab Vedotin and Pembrolizumab for bladder cancer

Presentation Description: Real world experiences in targeted chemotherapy and immunotherapy combination regimens.
Discussion of common adverse events as well as management, particularly focused on dose modification and early intervention for longevity on therapy.
Clinical pearls for APPs treating bladder cancer with novel therapies.